Breaking News, Collaborations & Alliances

Pfizer, Protalix in Gaucher Pact

Pfizer and Protalix have entered into an agreement to develop and commercialize taliglucerase alfa

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pfizer and Protalix have entered into an agreement to develop and commercialize taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase (GCD) in development for the potential treatment of Gaucher’s disease. Pfizer will receive exclusive worldwide licensing rights for the commercialization of taliglucerase alfa, while Protalix will retain the exclusive commercialization rights in Israel. Taliglucerase alfa is the first enzyme replacement therapy derived from a proprietary plant cell...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters